Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer.
نویسندگان
چکیده
AIM This study aimed to assess the efficacy and safety of oral metronomic chemotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS From January 2011 to February 2013, 60 patients with mCRPC received daily metronomic oral cyclophosphamide (50 mg qd), dexamethasone (1 mg qd) and celecoxib (200 mg bid). Among them 49 patients who met the preset inclusion criteria were included in this retrospective study. Adverse events and activity for reducing serum prostate-specific antigen (PSA) levels, Response Evaluation Criteria in Solid Tumor responses and symptomatic responses were reviewed. The primary endpoints were PSA response rate and time to PSA progression (TTPSA). RESULTS Twenty-two patients had previous exposure to docetaxel. The median age was 71 years (range, 49-88) with a median Eastern Cooperative Oncology Group performance of 1 (range, 0-2). The Gleason score was 8 or more in 41 patients (84%) with a median baseline serum PSA of 32.1 ng/mL (range, 1.2-743.0). The PSA response rate was 39%. With a median follow-duration of 17.5 months, the median TTPSA was 5.2 months (95% CI: 3.1-7.4). The median time to composite progression was 3.9 months (95% CI: 2.2-5.6) and a median overall survival was 13.3 months (95% CI: 9.5-17.1 months). There were no significant differences in the TTPSA between the pre- and post-docetaxel groups. Grade 3-4 AEs occurred only in six patients. CONCLUSION Metronomic oral cyclophosphamide chemotherapy is safe, well-tolerated and shows promising activity against mCRPC.
منابع مشابه
Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
PURPOSE Cyclophosphamide is a bifunctional alkylating agent long associated with immune activation. Continuous, uninterrupted, low (so-called metronomic) doses of cyclophosphamide can lead to enhanced immunity against a variety of antigens possibly by targeting regulatory T cells and/or tumor angiogenesis. In this study we tested the observations from animal models and evaluated the safety and ...
متن کاملSalvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.
OBJECTIVE To investigate the activity and toxicity of metronomic chemotherapy with low-dose oral cyclophosphamide (CTX) and methotrexate (MTX) in patients with metastatic CRPC that progresses after docetaxel. Patients with castration-resistant prostate cancer (CRPC) that progresses after docetaxel may benefit from receiving further chemotherapy. METHODS Patients were treated with CTX 50 mg/d ...
متن کاملComplete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
متن کامل
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
PURPOSE The aims of the present study were to evaluate the clinical activity and the pharmacodynamic profile of the novel schedule of a single i.v. standard dose of cyclophosphamide (CTX) immediately followed by an oral metronomic CTX regimen with celecoxib (CXB) and dexamethasone (DEX) in advanced hormone-refractory prostate cancer patients. EXPERIMENTAL DESIGN Twenty-eight patients (68% doc...
متن کاملCancer Therapy: Clinical Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer
Purpose: The aims of the present study were to evaluate the clinical activity and the pharmacodynamic profile of the novel schedule of a single i.v. standard dose of cyclophosphamide (CTX) immediately followed by an oral metronomic CTX regimen with celecoxib (CXB) and dexamethasone (DEX) in advanced hormone-refractory prostate cancer patients. ExperimentalDesign:Twenty-eight patients (68%doceta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Asia-Pacific journal of clinical oncology
دوره 13 3 شماره
صفحات -
تاریخ انتشار 2017